Zymeworks (NYSE:ZYME) Shares Up 3.5%

Zymeworks Inc. (NYSE:ZYME)’s stock price shot up 3.5% during mid-day trading on Friday . The company traded as high as $8.97 and last traded at $8.97. 36,851 shares changed hands during trading, a decline of 93% from the average session volume of 562,782 shares. The stock had previously closed at $8.67.

Zymeworks Stock Up 2.0 %

The stock has a fifty day simple moving average of $10.81 and a two-hundred day simple moving average of $9.53.

Zymeworks (NYSE:ZYME) last issued its earnings results on Wednesday, March 6th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.19. Zymeworks had a negative return on equity of 26.20% and a negative net margin of 156.12%. The firm had revenue of $16.93 million for the quarter, compared to the consensus estimate of $18.32 million. Equities research analysts expect that Zymeworks Inc. will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Gladius Capital Management LP raised its position in Zymeworks by 36.5% during the 3rd quarter. Gladius Capital Management LP now owns 3,940 shares of the company’s stock worth $25,000 after purchasing an additional 1,053 shares during the last quarter. SummerHaven Investment Management LLC raised its position in shares of Zymeworks by 1.4% in the 4th quarter. SummerHaven Investment Management LLC now owns 87,509 shares of the company’s stock worth $909,000 after acquiring an additional 1,199 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Zymeworks by 3.0% in the 4th quarter. Franklin Resources Inc. now owns 44,182 shares of the company’s stock worth $459,000 after acquiring an additional 1,293 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Zymeworks by 6.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,958 shares of the company’s stock worth $290,000 after acquiring an additional 1,748 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Zymeworks by 15.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,313 shares of the company’s stock worth $139,000 after acquiring an additional 1,752 shares in the last quarter. 92.89% of the stock is owned by institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.